18
Participants
Start Date
July 7, 2022
Primary Completion Date
December 15, 2024
Study Completion Date
April 15, 2025
Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
"Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2,Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle."
Tianjin Medical University Cancer Insititute & Hospital, Tianjin
Collaborators (1)
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY
Tianjin Medical University Cancer Institute and Hospital
OTHER